{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Royston+Smith&max-AnswerDate=2019-04-24&humanIndexable=true&min-ddpCreated=2019-01-10T20%3A12%3A59.837Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMemberPrinted.=Royston+Smith&max-AnswerDate=2019-04-24&humanIndexable=true&min-ddpCreated=2019-01-10T20%3A12%3A59.837Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Royston+Smith&max-AnswerDate=2019-04-24&humanIndexable=true&min-ddpCreated=2019-01-10T20%3A12%3A59.837Z&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Royston+Smith&_page=0&max-AnswerDate=2019-04-24&humanIndexable=true&min-ddpCreated=2019-01-10T20%3A12%3A59.837Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Royston+Smith&max-AnswerDate=2019-04-24&humanIndexable=true&min-ddpCreated=2019-01-10T20%3A12%3A59.837Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Royston+Smith&max-AnswerDate=2019-04-24&humanIndexable=true&min-ddpCreated=2019-01-10T20%3A12%3A59.837Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1122558", "AnsweringBody" : [{"_value" : "Cabinet Office"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1122558/answer", "answerText" : {"_value" : "<p>Our Places for Growth programme will relocate Civil Servants out of London, with at least 1,000 roles moved by 2022 and thousands more by 2030.<\/p><p> <\/p><p>This in addition to the twelve new public bodies that will be located outside of London.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4441", "label" : {"_value" : "Biography information for Oliver Dowden"}
        }
        , "answeringMemberConstituency" : {"_value" : "Hertsmere"}
        , "answeringMemberPrinted" : {"_value" : "Oliver Dowden"}
        , "dateOfAnswer" : {"_value" : "2019-04-24", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-04-24T15:41:57.183Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "53"}
      , "answeringDeptShortName" : {"_value" : "Cabinet Office"}
      , "answeringDeptSortName" : {"_value" : "Cabinet Office"}
      , "date" : {"_value" : "2019-04-11", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Civil Servants: Location"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "What steps are his department taking to move civil service jobs out of London in line with the Government\u2019s industrial strategy.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4478", "label" : {"_value" : "Biography information for Royston Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Southampton, Itchen"}
      , "tablingMemberPrinted" : [{"_value" : "Royston Smith"}
      ], "uin" : "910478"}
    , {"_about" : "http://data.parliament.uk/resources/1110380", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1110380/answer", "answerText" : {"_value" : "<p>The Government does not distinguish between acute and repeat prescriptions. Over two million prescription items \u2013 acute and repeat - are dispensed in England alone every day. Medicine supply problems can occur for a wide variety of reasons, and the Department has well established routine procedures to deal with shortages, from whatever cause, working closely with manufacturers, the National Health Service and patient groups.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
        }
        , "answeringMemberConstituency" : {"_value" : "South Ribble"}
        , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
        , "dateOfAnswer" : {"_value" : "2019-04-12", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-04-12T14:15:30.21Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-04-08", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Prescriptions"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what his Department's policy is to ensure that people who require repeat prescriptions are able to have access to the medicine they require.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4478", "label" : {"_value" : "Biography information for Royston Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Southampton, Itchen"}
      , "tablingMemberPrinted" : [{"_value" : "Royston Smith"}
      ], "uin" : "242193"}
    , {"_about" : "http://data.parliament.uk/resources/1110381", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1110381/answer", "answerText" : {"_value" : "<p>Whether a prescription is a repeat or not is not indicated on the prescription therefore it is not recorded centrally.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
        }
        , "answeringMemberConstituency" : {"_value" : "South Ribble"}
        , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
        , "dateOfAnswer" : {"_value" : "2019-04-11", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-04-11T16:59:25.397Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-04-08", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Prescriptions"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, how many people are registered for repeat prescriptions.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4478", "label" : {"_value" : "Biography information for Royston Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Southampton, Itchen"}
      , "tablingMemberPrinted" : [{"_value" : "Royston Smith"}
      ], "uin" : "242194"}
    , {"_about" : "http://data.parliament.uk/resources/1110385", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1110385/answer", "answerText" : {"_value" : "<p>Whether a prescription is a repeat or not is not indicated on the prescription. Therefore, the cost to the public purse of free repeat prescriptions is not recorded centrally. However, we know, for the past three years, that around almost 90% of prescriptions are dispensed free of charge.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
        }
        , "answeringMemberConstituency" : {"_value" : "South Ribble"}
        , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
        , "dateOfAnswer" : {"_value" : "2019-04-12", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-04-12T14:14:47.897Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-04-08", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Prescriptions"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what the cost to the public purse has been of free repeat prescriptions in each of the last three years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4478", "label" : {"_value" : "Biography information for Royston Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Southampton, Itchen"}
      , "tablingMemberPrinted" : [{"_value" : "Royston Smith"}
      ], "uin" : "242195"}
    , {"_about" : "http://data.parliament.uk/resources/1108993", "AnsweringBody" : [{"_value" : "Department for Transport"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1108993/answer", "answerText" : {"_value" : "<p>I apologise that due to an administrative error, this question was not answered. This has now been rectified.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3991", "label" : {"_value" : "Biography information for Jesse Norman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Hereford and South Herefordshire"}
        , "answeringMemberPrinted" : {"_value" : "Jesse Norman"}
        , "dateOfAnswer" : {"_value" : "2019-04-04", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-04-04T11:25:37.83Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "27"}
      , "answeringDeptShortName" : {"_value" : "Transport"}
      , "answeringDeptSortName" : {"_value" : "Transport"}
      , "date" : {"_value" : "2019-04-02", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Department for Transport: Written Questions"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Transport, when he plans to respond to Question 210578 on Cycling: Safety tabled on 21 January 2019 by the hon. Member for Southampton Itchen.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4478", "label" : {"_value" : "Biography information for Royston Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Southampton, Itchen"}
      , "tablingMemberPrinted" : [{"_value" : "Royston Smith"}
      ], "uin" : "240040"}
    , {"_about" : "http://data.parliament.uk/resources/1078455", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1078455/answer", "answerText" : {"_value" : "<p>The Department is aware that supplies of naproxen tablets were limited during January and early February due to a manufacturing issue with the active pharmaceutical ingredient. During this time, we worked closely with all suppliers of naproxen tablets to expedite further deliveries.<\/p><p>Supplies of naproxen tablets are currently available in volumes sufficient to meet national requirements. We will continue to work closely with all manufacturers of naproxen tablets to monitor the overall supply situation to ensure supplies continue to remain available. We have provided updates about the naproxen supply situation to the National Health Service via primary and secondary care networks and will continue to do this.<\/p><p>We understand that naproxen, and other medicines, are vitally important to many people in this country. Our contingency plans include sensible mitigations for medicines that come to the United Kingdom from or via the European Union to ensure that the supply of medicines for patients is not disrupted.<\/p><p>The Department is unable to discuss the specific arrangements for naproxen, because to reassure companies engaging in our contingency plans, we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department\u2019s programme.<\/p><p>A comprehensive plan has been put in place in the form of a multi-layered approach to minimise any supply disruption:<\/p><p>- securing, via the Department for Transport, additional roll on roll off freight capacity (away from the short straits) for goods to continue to come into the UK from 29 March;<\/p><p>- buffer stocks and stockpiling (where this is practical) or asking industry to build up buffer stocks in the UK before 29 March;<\/p><p>- buying extra warehouse space for the additional stock to be held in;<\/p><p>- supporting companies in booking space on aircraft for products which require an immediate shipment due to short shelf-life or specific storage conditions;<\/p><p>- making changes to, or clarifications of, certain regulatory requirements so that companies can continue to sell their products in the UK even if we have \u2018no deal\u2019; and<\/p><p>- strengthening the processes and resources used to deal with shortages in the event that they do occur.<\/p><p>No one of these measures will work on its own. A combination of securing freight, buffer stocks, stockpiling and warehousing, regulatory flexibility, and clinical assessment and decision making, will be required help to ensure the continuation of medical supplies.<\/p><p>Throughout enacting our plans, the response from pharmaceutical companies has been hugely positive. Companies share our aims of ensuring continuity of medicines\u2019 supply for patients is maintained and able to cope with any potential delays at the border that may arise in the event the UK leaves the EU without a deal.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1585", "label" : {"_value" : "Biography information for Stephen Hammond"}
        }
        , "answeringMemberConstituency" : {"_value" : "Wimbledon"}
        , "answeringMemberPrinted" : {"_value" : "Stephen Hammond"}
        , "dateOfAnswer" : {"_value" : "2019-03-06", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "226170"}
        , {"_value" : "226171"}
        , {"_value" : "226708"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-03-06T11:02:14.48Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-02-27", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Naproxen"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the availability of naproxen on the NHS.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4478", "label" : {"_value" : "Biography information for Royston Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Southampton, Itchen"}
      , "tablingMemberPrinted" : [{"_value" : "Royston Smith"}
      ], "uin" : "226707"}
    , {"_about" : "http://data.parliament.uk/resources/1078456", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1078456/answer", "answerText" : {"_value" : "<p>The Department is aware that supplies of naproxen tablets were limited during January and early February due to a manufacturing issue with the active pharmaceutical ingredient. During this time, we worked closely with all suppliers of naproxen tablets to expedite further deliveries.<\/p><p>Supplies of naproxen tablets are currently available in volumes sufficient to meet national requirements. We will continue to work closely with all manufacturers of naproxen tablets to monitor the overall supply situation to ensure supplies continue to remain available. We have provided updates about the naproxen supply situation to the National Health Service via primary and secondary care networks and will continue to do this.<\/p><p>We understand that naproxen, and other medicines, are vitally important to many people in this country. Our contingency plans include sensible mitigations for medicines that come to the United Kingdom from or via the European Union to ensure that the supply of medicines for patients is not disrupted.<\/p><p>The Department is unable to discuss the specific arrangements for naproxen, because to reassure companies engaging in our contingency plans, we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department\u2019s programme.<\/p><p>A comprehensive plan has been put in place in the form of a multi-layered approach to minimise any supply disruption:<\/p><p>- securing, via the Department for Transport, additional roll on roll off freight capacity (away from the short straits) for goods to continue to come into the UK from 29 March;<\/p><p>- buffer stocks and stockpiling (where this is practical) or asking industry to build up buffer stocks in the UK before 29 March;<\/p><p>- buying extra warehouse space for the additional stock to be held in;<\/p><p>- supporting companies in booking space on aircraft for products which require an immediate shipment due to short shelf-life or specific storage conditions;<\/p><p>- making changes to, or clarifications of, certain regulatory requirements so that companies can continue to sell their products in the UK even if we have \u2018no deal\u2019; and<\/p><p>- strengthening the processes and resources used to deal with shortages in the event that they do occur.<\/p><p>No one of these measures will work on its own. A combination of securing freight, buffer stocks, stockpiling and warehousing, regulatory flexibility, and clinical assessment and decision making, will be required help to ensure the continuation of medical supplies.<\/p><p>Throughout enacting our plans, the response from pharmaceutical companies has been hugely positive. Companies share our aims of ensuring continuity of medicines\u2019 supply for patients is maintained and able to cope with any potential delays at the border that may arise in the event the UK leaves the EU without a deal.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1585", "label" : {"_value" : "Biography information for Stephen Hammond"}
        }
        , "answeringMemberConstituency" : {"_value" : "Wimbledon"}
        , "answeringMemberPrinted" : {"_value" : "Stephen Hammond"}
        , "dateOfAnswer" : {"_value" : "2019-03-06", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "226170"}
        , {"_value" : "226171"}
        , {"_value" : "226707"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-03-06T11:02:14.547Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-02-27", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Naproxen"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of stocks of naproxen held by the NHS in the event that the UK leaves the EU.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4478", "label" : {"_value" : "Biography information for Royston Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Southampton, Itchen"}
      , "tablingMemberPrinted" : [{"_value" : "Royston Smith"}
      ], "uin" : "226708"}
    , {"_about" : "http://data.parliament.uk/resources/1077606", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1077606/answer", "answerText" : {"_value" : "<p>The Department is aware that supplies of naproxen tablets were limited during January and early February due to a manufacturing issue with the active pharmaceutical ingredient. During this time, we worked closely with all suppliers of naproxen tablets to expedite further deliveries.<\/p><p>Supplies of naproxen tablets are currently available in volumes sufficient to meet national requirements. We will continue to work closely with all manufacturers of naproxen tablets to monitor the overall supply situation to ensure supplies continue to remain available. We have provided updates about the naproxen supply situation to the National Health Service via primary and secondary care networks and will continue to do this.<\/p><p>We understand that naproxen, and other medicines, are vitally important to many people in this country. Our contingency plans include sensible mitigations for medicines that come to the United Kingdom from or via the European Union to ensure that the supply of medicines for patients is not disrupted.<\/p><p>The Department is unable to discuss the specific arrangements for naproxen, because to reassure companies engaging in our contingency plans, we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department\u2019s programme.<\/p><p>A comprehensive plan has been put in place in the form of a multi-layered approach to minimise any supply disruption:<\/p><p>- securing, via the Department for Transport, additional roll on roll off freight capacity (away from the short straits) for goods to continue to come into the UK from 29 March;<\/p><p>- buffer stocks and stockpiling (where this is practical) or asking industry to build up buffer stocks in the UK before 29 March;<\/p><p>- buying extra warehouse space for the additional stock to be held in;<\/p><p>- supporting companies in booking space on aircraft for products which require an immediate shipment due to short shelf-life or specific storage conditions;<\/p><p>- making changes to, or clarifications of, certain regulatory requirements so that companies can continue to sell their products in the UK even if we have \u2018no deal\u2019; and<\/p><p>- strengthening the processes and resources used to deal with shortages in the event that they do occur.<\/p><p>No one of these measures will work on its own. A combination of securing freight, buffer stocks, stockpiling and warehousing, regulatory flexibility, and clinical assessment and decision making, will be required help to ensure the continuation of medical supplies.<\/p><p>Throughout enacting our plans, the response from pharmaceutical companies has been hugely positive. Companies share our aims of ensuring continuity of medicines\u2019 supply for patients is maintained and able to cope with any potential delays at the border that may arise in the event the UK leaves the EU without a deal.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1585", "label" : {"_value" : "Biography information for Stephen Hammond"}
        }
        , "answeringMemberConstituency" : {"_value" : "Wimbledon"}
        , "answeringMemberPrinted" : {"_value" : "Stephen Hammond"}
        , "dateOfAnswer" : {"_value" : "2019-03-06", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "226171"}
        , {"_value" : "226707"}
        , {"_value" : "226708"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-03-06T11:02:14.37Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-02-26", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Naproxen"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 9 January 2019 to Question 205406 on Naproxen, what progress has been made on securing additional deliveries of naproxen.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4478", "label" : {"_value" : "Biography information for Royston Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Southampton, Itchen"}
      , "tablingMemberPrinted" : [{"_value" : "Royston Smith"}
      ], "uin" : "226170"}
    , {"_about" : "http://data.parliament.uk/resources/1077615", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1077615/answer", "answerText" : {"_value" : "<p>The Department is aware that supplies of naproxen tablets were limited during January and early February due to a manufacturing issue with the active pharmaceutical ingredient. During this time, we worked closely with all suppliers of naproxen tablets to expedite further deliveries.<\/p><p>Supplies of naproxen tablets are currently available in volumes sufficient to meet national requirements. We will continue to work closely with all manufacturers of naproxen tablets to monitor the overall supply situation to ensure supplies continue to remain available. We have provided updates about the naproxen supply situation to the National Health Service via primary and secondary care networks and will continue to do this.<\/p><p>We understand that naproxen, and other medicines, are vitally important to many people in this country. Our contingency plans include sensible mitigations for medicines that come to the United Kingdom from or via the European Union to ensure that the supply of medicines for patients is not disrupted.<\/p><p>The Department is unable to discuss the specific arrangements for naproxen, because to reassure companies engaging in our contingency plans, we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department\u2019s programme.<\/p><p>A comprehensive plan has been put in place in the form of a multi-layered approach to minimise any supply disruption:<\/p><p>- securing, via the Department for Transport, additional roll on roll off freight capacity (away from the short straits) for goods to continue to come into the UK from 29 March;<\/p><p>- buffer stocks and stockpiling (where this is practical) or asking industry to build up buffer stocks in the UK before 29 March;<\/p><p>- buying extra warehouse space for the additional stock to be held in;<\/p><p>- supporting companies in booking space on aircraft for products which require an immediate shipment due to short shelf-life or specific storage conditions;<\/p><p>- making changes to, or clarifications of, certain regulatory requirements so that companies can continue to sell their products in the UK even if we have \u2018no deal\u2019; and<\/p><p>- strengthening the processes and resources used to deal with shortages in the event that they do occur.<\/p><p>No one of these measures will work on its own. A combination of securing freight, buffer stocks, stockpiling and warehousing, regulatory flexibility, and clinical assessment and decision making, will be required help to ensure the continuation of medical supplies.<\/p><p>Throughout enacting our plans, the response from pharmaceutical companies has been hugely positive. Companies share our aims of ensuring continuity of medicines\u2019 supply for patients is maintained and able to cope with any potential delays at the border that may arise in the event the UK leaves the EU without a deal.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1585", "label" : {"_value" : "Biography information for Stephen Hammond"}
        }
        , "answeringMemberConstituency" : {"_value" : "Wimbledon"}
        , "answeringMemberPrinted" : {"_value" : "Stephen Hammond"}
        , "dateOfAnswer" : {"_value" : "2019-03-06", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "226170"}
        , {"_value" : "226707"}
        , {"_value" : "226708"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-03-06T11:02:14.433Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-02-26", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Naproxen"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 16 January 2019 to Question 209362, what further discussions his Department has had with the health sector on the supply of Naproxen.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4478", "label" : {"_value" : "Biography information for Royston Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Southampton, Itchen"}
      , "tablingMemberPrinted" : [{"_value" : "Royston Smith"}
      ], "uin" : "226171"}
    , {"_about" : "http://data.parliament.uk/resources/1064691", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1064691/answer", "answerText" : {"_value" : "<p>Local areas are beginning to work up plans for the implementation of lung health checks in their area, and funding has been made available to enable projects to start in 2019-20. Total costs are just under £70 million and will pay for nurses, radiographers and radiologists to provide lung health check appointments and low dose computed tomography (CT) scans.<\/p><p> <\/p><p>In the ten initial roll-out sites which include Wessex Cancer Alliance (Southampton Care Commissioning Group) there are approximately 600,000 eligible patients, who between them will require a total of 200,000 CT scans.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2019-02-28", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-02-28T11:51:35.48Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-02-21", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Lung Diseases: Screening"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the NHS Long Term Plan, what the timeframe is for the introduction of lung health checks in Southampton Care Commissioning Group.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4478", "label" : {"_value" : "Biography information for Royston Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Southampton, Itchen"}
      , "tablingMemberPrinted" : [{"_value" : "Royston Smith"}
      ], "uin" : "224354"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Royston+Smith&_page=1&max-AnswerDate=2019-04-24&humanIndexable=true&min-ddpCreated=2019-01-10T20%3A12%3A59.837Z", "page" : 0, "startIndex" : 1, "totalResults" : 37, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}